In addition to taking an unbiased look at novel associations that might affect CRC viability by sensitizing cells to chemotherapy through modulation of mitochondrial FOXO3a-dependent chemoresistance, we will provide insight into genes and pathways involved in tumor resistance to support the development of more tailored interventions in CRC patients. The gene discussed is FOXO3; the disease is colorectal carcinoma.